Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) inhibitors are crucial in cancer therapy.
• Acquired resistance to EGFR inhibitors is a major clinical challenge.
• Targeting downstream signaling pathways may overcome resistance.

Purpose of the Study:

• To evaluate the antitumour efficacy of enzastaurin, a PKCbeta inhibitor.
• To assess enzastaurin's ability to overcome resistance to anti-EGFR drugs.
• To investigate the combination therapy of enzastaurin and gefitinib in sensitive and resistant cancer models.

Main Methods:

• In vitro studies using human colon (GEO) and prostate (PC3) cancer cells, including gefitinib-resistant variants (GEO-GR, PC3-GR).
• In vivo studies using nude mice xenograft models with GEO and GEO-GR tumors.
• Analysis of signaling protein expression (pAkt, pp70S6K, pGSK3beta) and VEGF levels.

Main Results:

• Enzastaurin demonstrated marked inhibitory activity against sensitive and resistant cancer cells.
• Enzastaurin inhibited key signaling proteins (pAkt, pp70S6K, pGSK3beta) and VEGF.
• Enzastaurin exhibited a cooperative effect with gefitinib in both sensitive and resistant cells, both in vitro and in vivo.
• In vivo studies showed increased median survival and reduced tumor growth in mice treated with enzastaurin and gefitinib.

Conclusions:

• Enzastaurin effectively inhibits cancer cell growth and overcomes resistance to EGFR inhibitors.
• Enzastaurin cooperates with gefitinib, suggesting a promising therapeutic strategy for EGFR-resistant tumors.
• Targeting VEGFR-dependent PKCbeta signaling with enzastaurin provides a rationale for clinical development in resistant cancers.